Abstracts tagged "autoantigens"

Abstract Number: 1730 • 2014 ACR/ARHP Annual Meeting
Identification of Novel Scleroderma –associated Antigens and Development of an Autoantibody Assay Panel Enabling Their Subsequent Validation
Hans-Dieter Zucht¹, Petra Budde¹, Peter Schulz-Knappe¹, Nicolas Hunzelmann², Karsten Conrad³ and Prof. Dr. Matthias Schneider⁴, ¹Protagen AG, Dortmund, Germany, ²Department of Dermatology, University of Cologne, Cologne, Germany, ³Medizinische Fakultät Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany, ⁴Department of Rheumatology, Univ. Duesseldorf, Duesseldorf, Germany
Background/Purpose: Scleroderma (systemic sclerosis or SSc) has a highly variable clinical presentation and course resulting in difficulties for disease management. When SSc is suspected, autoantibodies…
Abstract Number: 1610 • 2014 ACR/ARHP Annual Meeting
New Autoantigens Associated with Lupus Nephritis
Sachiko Onishi¹, Yuki Tanaka², Tatsuhiko Miyazaki³, Jun Ishizaki¹, Takuya Matsumoto¹, Endy Adnan¹, Hitoshi Yamasaki⁴, Koichiro Suemori¹, Takafumi Okura⁵, Masaki Yasukawa¹ and Hitoshi Hasegawa⁶, ¹Department of Hematology, Clinical Immunology, and Infectious Diseases, Ehime University Graduate School of Medicine, Toon, Japan, ²Integrated Center for Sciences, Ehime University, Toon, Japan, ³Division of Pathology, Gifu University Hospital, Gifu, Japan, ⁴Department of Hematology, Clinical Immunology, and Infectious Disease, Ehime University Graduate School of Medicine, Toon, Japan, ⁵Department of Cardiology, Pulmonology, Hypertension and Nephrology, Ehime University Graduate School of Medicine, Toon, Japan, ⁶Department of Hematology, Clinical Immunology and Infectious Diseases, Ehime University Graduate School of Medicine, Toon, Japan
[Background/Purpose ] Systemic lupus erythematosus (SLE) is characterized by the production of a variety of autoantibodies and is considered a prototype immune complex disease. Anti-dsDNA…
Abstract Number: 878 • 2014 ACR/ARHP Annual Meeting
Luminex and Autoantigen Microarray Analysis of Sera from Patients with Diffuse Cutaneous Systemic Sclerosis Reveals Changes Associated with Imatinib Mesylate Treatment
D. James Haddon¹, Hannah Wand², Paul J. Utz¹, Robert F. Spiera³, Jessica K. Gordon³ and Lorinda Chung⁴, ¹Medicine, Stanford University School of Medicine, Stanford, CA, ²Stanford University School of Medicine, Stanford, CA, ³Rheumatology, Hospital for Special Surgery, New York, NY, ⁴Immunology and Rheumatology, Stanford University School of Medicine, Palo Alto, CA
Background/Purpose Tyrosine kinase inhibitors (TKIs), including imatinib mesylate, have been studied for the treatment of diffuse cutaneous Systemic Sclerosis (dcSSc). In a previously reported single…
Abstract Number: 339 • 2014 ACR/ARHP Annual Meeting
Toll-like Receptor Dependent Autoantigens and Vesicles from P.Gingivalis in Animal Models of RA to Modulate Collagen and Collagen Antibody Induced Arthritis
Christina Grimm¹, Bianka Marklein¹, Gerd Burmester^1,2 and Karl Skriner³, ¹Department of Rheumatology and Clinical Immunology, Charité - Universitätsmedizin Berlin, Berlin, Germany, ²Charité – University Medicine Berlin, Berlin, Germany, ³Department of Rheumatology and Clinical Immunology, Germany, Charité - Universitätsmedizin Berlin, Berlin, Germany
Background/Purpose A variety of animal models suggest that TLR signaling is important in the pathogenesis of RA and the generation of specific autoantibodies. This study…
Abstract Number: 87 • 2014 ACR/ARHP Annual Meeting
Association of TRIM21 (RO52) Polymorphisms with Systemic Lupus Erythematosus in a Japanese Population
Misaki Hidaka¹, Aya Kawasaki¹, Hiroshi Furukawa², Yuya Kondo³, Satoshi Ito⁴, Isao Matsumoto⁵, Makio Kusaoi⁶, Hirofumi Amano⁶, Akiko Suda⁷, Keigo Setoguchi⁸, Tatsuo Nagai⁹, Kota Shimada¹⁰, Shoji Sugii¹⁰, Akira Okamoto¹¹, Noriyuki Chiba¹², Eiichi Suematsu¹³, Masao Katayama¹⁴, Akiko Okamoto¹⁵, Hajime Kono¹⁵, Shigeru Ohno⁷, Shunsei Hirohata¹⁶, Shouhei Nagaoka¹⁷, Yoshinari Takasaki¹⁸, Hiroshi Hashimoto¹⁹, Shigeto Tohma², Takayuki Sumida³ and Naoyuki Tsuchiya¹, ¹Molecular and Genetic Epidemiology Laboratory, Faculty of Medicine, University of Tsukuba, Tsukuba, Japan, ²Clinical Research Center for Allergy and Rheumatology, Sagamihara Hospital, National Hospital Organization, Sagamihara, Japan, ³Department of Internal Medicine, Faculty of Medicine, University of Tsukuba, Tsukuba, Japan, ⁴Department of Rheumatology, Niigata Rheumatic Center, Shibata, Japan, ⁵Department of Interenal Medicine, Faculty of Medicine, University of Tsukuba, Tsukuba, Japan, ⁶Department of Rheumatology and Internal Medicine, Juntendo University, Tokyo, Japan, ⁷Center for Rheumatic Diseases, Yokohama City University Medical Center, Yokohama, Japan, ⁸Allergy and Immunological Diseases, Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, Tokyo, Japan, ⁹Department of Rheumatology and Infectious Diseases, Kitasato University School of Medicine, Sagamihara, Japan, ¹⁰Department of Rheumatic Diseases, Tokyo Metropolitan Tama Medical Center, Tokyo, Japan, ¹¹Department of Rheumatology,, Himeji Medical Center, National Hospital Organization, Himeji, Japan, ¹²Department of Rheumatology, Morioka Hospital, National Hospital Organization, Morioka, Japan, ¹³Department of Internal Medicine and Rheumatology, Clinical Research Institute, Kyushu Medical Center, National Hospital Organization, Fukuoka, Japan, ¹⁴Division of Rheumatology, Department of Internal Medicine, Nagoya Medical Center, National Hospital Organization, Nagoya City, Aichi, Japan, ¹⁵Department of Internal Medicine, Teikyo University School of Medicine, Tokyo, Japan, ¹⁶Int Med/Rheumatol & Infec Dis, Kitasato University School of Medicine, Sagamihara, Japan, ¹⁷Department of Rheumatology, Yokohama Minami Kyousai Hospital, Yokohama, Japan, ¹⁸Department of Rheumatology, Juntendo University School of Medicine, Tokyo, Japan, ¹⁹Juntendo University School of Medicine, Tokyo, Japan
Background/Purpose TRIM21, also referred to as Ro52 or SS-A1, belongs to the tripartite motif-containing (TRIM) family. TRIM21 is not only important as an autoantigen, but…
Abstract Number: 1778 • 2013 ACR/ARHP Annual Meeting
Physical Interactions Between Histidyl-tRNA Synthetase and Endogenous/Exogenous Alarmins Enhance Immunogenicity In a Model Of Antigen-Induced Myositis
Irina Fernandez¹, Lisa Harlow², William Ridgway³ and Dana P. Ascherman⁴, ¹Rheumatology, University of Miami, Miami, FL, ²Rheumatology and Clinical Immunology, University of Miami Miller School of Medicine, Miami, FL, ³Immunology, Allergy and Rheumatology, University of Cincinnati, Cincinnati, OH, ⁴Medicine/Rheumatology, University of Miami Miller School of Medicine, Miami, FL
Objective: To assess the biological interplay between histidyl-tRNA synthetase (HRS) and different endogenous/exogenous ligands capable of generating signals through MyD88-dependent receptor systems in idiopathic inflammatory…
Abstract Number: 1575 • 2013 ACR/ARHP Annual Meeting
Identification Of Novel Distinct Autoantigen Clusters Reflecting The Heterogeneity Of Systemic Lupus Erythematosus
Petra Budde¹, Angelika Lueking¹, Stefan Vordenbäumen², Heike Göhler¹, Martin Gamer¹, Klaus Marquardt¹, Anna Telaar¹, Daniel Chamrad¹, Carmen Theek¹, Peter Schulz-Knappe¹ and Matthias Schneider², ¹Protagen AG, Dortmund, Germany, ²Department of Endocrinology, Diabetes and Rheumatology, Heinrich-Heine-University Duesseldorf, Duesseldorf, Germany
Background/Purpose: Diagnosis of systemic lupus erythematosus (SLE) is based on a combination of clinical findings and laboratory evidence such as anti-nuclear autoantibodies (ANA), anti-Smith and…
Abstract Number: 913 • 2013 ACR/ARHP Annual Meeting
High Throughput Epitope Mapping Of Autoantibodies In BXD2 Mice Reveals The Generation Of Autoantibodies Against Citrullinated Antigens At The Predicted Major Immunogenic Sites
Jennie Hamilton¹, Qi Wu², PingAr Yang², Hui-Chen Hsu³ and John D. Mountz⁴, ¹University of Alabama at Birmingham, Birmingham, AL, ²Division of Clinical Immunology and Rheumatology, Department of Medicine, University of Alabama at Birmingham, Birmingham, AL, ³Department of Medicine, Clinical Immunology & Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ⁴Dept of Med/Rheumatology Div, University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Increased polyreactive B cells have been identified in patients with systemic lupus erythematous (SLE) and rheumatoid arthritis (RA). Such autoantibodies (autoAbs) were also identified…
Abstract Number: 630 • 2013 ACR/ARHP Annual Meeting
Galectin-3-Binding Protein Is Highly Increased On Circulating Microparticles In SLE Patients and Co-Localizes With IgG In Glomerular Deposits In Human Lupus Nephritis
Christoffer T. Nielsen^1,2, Ole Østergaard³, Ole Petter Rekvig⁴, Gunnar K. Sturfelt⁵, Søren Jacobsen⁶ and Niels H. H. Heegaard⁷, ¹Department of Clinical Biochemistry, Immunology & Genetics, Statens Serum Institut, Copenhagen S, Denmark, ²Infectious Diseases and Rheumatology, University Hospital Rigshospitalet, Copenhagen, Denmark, ³Department of Clinical Biochemistry, Immunology & Genetics, Statens Serum Institute, Copenhagen S, Denmark, ⁴Department of Biochemistry and Medical Biology, University Hospital, Tromsø, Norway, ⁵Department of Rheumatology, University Hospital Lund, Lund, Sweden, ⁶Department of Rheumatology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark, ⁷Department of Clinical Biochemistry, Immunology & Genetics, Statens Serum Institut, Copenhagen, Denmark
Background/Purpose: The origin of autoantigens in glomerular immune complex (IC) deposits in lupus nephritis patients is unknown. They may derive from the circulation (microparticle (MP)-ICs…
Abstract Number: 37 • 2013 ACR/ARHP Annual Meeting
Follicular Entry Of Lymphotoxin-Expressing B Cells Via Type I Interferon Disrupts Marginal Zone Barrier Integrity and Exacerbates Systemic Autoimmunity
Hao Li¹, Hui-Chen Hsu², Qi Wu³, Jun Li³, PingAr Yang³, Yang-Xin Fu⁴ and John D. Mountz⁵, ¹Dept. Med - Immunology/Rheumatology division, University of Alabama at Birmingham, Birmingham, AL, ²Birmingham VA Medical Center, Birmingham, AL, ³Division of Clinical Immunology and Rheumatology, Department of Medicine, University of Alabama at Birmingham, Birmingham, AL, ⁴Department of Pathology, The University of Chicago, Chicago, IL, ⁵Dept of Med/Rheumatology Div, University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Marginal zone macrophages (MZMs), a small subset of specialized splenic macrophages located in the MZ, act as final follicular entry barrier to clear apoptotic…
Abstract Number: 713 • 2012 ACR/ARHP Annual Meeting
Rpp25 Is a Major Target of Autoantibodies to the Th/to Complex As Measured by ELISA and a New Chemilumiscence Assay
Michael Mahler¹, Cristina Gascon², Sima Patel², Angela Ceribelli³, Edward K.L. Chan³ and Minoru Satoh⁴, ¹Research, INOVA Diagnostics, San Diego, CA, ²Research, INOVA Diagnostics, Inc., San Diego, CA, ³Oral Biology, University of Florida, Gainesville, FL, ⁴Medicine, University of Florida, Gainesville, FL
Background/Purpose: Anti-nuclear antibodies (ANA) play an important role in the diagnosis of systemic autoimmune diseases including systemic sclerosis (SSc). A significant portion of ANA in…
Abstract Number: 2577 • 2012 ACR/ARHP Annual Meeting
Characterization of Circulating Human B Cells That Bind Cyclic Citrullinated Peptide Antigens in Clinically Active Rheumatoid Arthritis
Gregg J. Silverman¹, John Jung², Jeffrey D. Greenberg³, Adam J. Pelzek⁴, Caroline Gronwall⁵ and Jaya Vas⁵, ¹Medical and Pathology, NYU School of Medicine, New York, NY, ²School of Medicine, NYU, New York, NY, ³New York Hospital for Joint Disease, New York, NY, ⁴School of Medicine, NYU School of Medicine, New York, NY, ⁵Rheumatology, NYU School of Medicine, New York, NY
Background/Purpose: Anti-citrullinated protein antibodies (ACPA) were first identified based on their high specificity for RA and now are commonly used as a diagnostic tool. Yet,…
Abstract Number: 1391 • 2012 ACR/ARHP Annual Meeting
Anti-Ku Autoantibodies in Systemic Lupus Erythematosus Versus Autoimmune Myositis As Measured by a Novel Chemiluminescence Assay
Michael Mahler¹, Jason Wu², Magdalena Szmyrka-Kaczmarek³, Andreas Swart⁴, Marvin J. Fritzler⁵, Jean-Luc Senécal⁶ and John G. Hanly⁷, ¹Research, INOVA Diagnostics, San Diego, CA, ²Research, INOVA Diagnostics, San Diego, ³Rheumatology, Wroclaw Medical University, Wroclaw, Poland, ⁴Rheumatology clinic Neuss, Neuss, Germany, ⁵Medicine, University of Calgary, Calgary, AB, Canada, ⁶Rheumatology, Hôpital Notre-Dame du CHUM, Montréal, QC, Canada, ⁷Division of Rheumatology, Dalhousie University and Capital Health, Halifax, NS, Canada
Background/Purpose: Autoantibodies targeting Ku, an abundant nuclear protein with DNA helicase activity, have been reported in patients with systemic autoimmune rheumatic diseases. Little is known…
Abstract Number: 1081 • 2012 ACR/ARHP Annual Meeting
Toll-Like Receptor 7, 8 and 9 Activation of Primary Human Cells by Lupus Immune Complexes Is Dependent On Interleukin 1 Receptor Associated Kinase 4 Activity
Aaron Winkler¹, Weiyong Sun¹, Ken Dower², Elizabeth A. Murphy¹, Julia Shin¹, Michael Luong¹, Michael J. Primiano¹, Varenka A. Rodriguez², Tatyana Souza¹, Lih-Ling Lin³, J. Perry Hall¹, Katherine Lee⁴, Vikram R. Rao¹ and Margaret Fleming¹, ¹Inflammation & Remodeling, Pfizer, Cambridge, MA, ²Inflammation and Remodeling, Pfizer, Cambridge, MA, ³Inflammation and Remodeling Research Unit, Pfizer, Cambridge, MA, ⁴Worldwide Medicinal Chemistry, Pfizer, Cambridge, MA
Background/Purpose: Genetic, in vitro and in vivo evidence strongly implicate the activation of nucleic acid sensing toll like receptors (TLR) 7, 8, and 9 in…
Abstract Number: 889 • 2012 ACR/ARHP Annual Meeting
Modeling Environmental and Genetic Determinants to Identify the Association of Risk Genes in Anti-Ro60-Mediated Injury: Relaxin Receptor I and Tumor Necrosis Factor
Joanne H. Reed¹, Paula S. Ramos², Jiri Zavadil³, Jill P. Buyon⁴ and Robert M. Clancy¹, ¹Medicine, New York University School of Medicine, New York, NY, ²Department of Medicine, Medical University of South Carolina, Charleston, SC, ³Pathology and Center for Health Informatics and Bioinformtics, New York University School of Medicine, New York, NY, ⁴Department of Medicine, New York University School of Medicine, New York, NY
Background/Purpose: Fetuses exposed to maternal anti-Ro60 antibodies can develop cardiac conduction abnormalities and life threatening cardiomyopathy; manifestations of neonatal lupus (NL). Recent data support an injury…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].